Br J Cancer. 2004 Oct 18;91(8):1420-4.

Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer.

Source

The City Hospital, Nottingham NG5 1PB, UK. schan2@ncht.trent.nhs.uk

Abstract

mTOR is a downstream mediator in the PI3K/Akt signalling pathway, which plays a critical role in regulating basic cellular functions. These include cell proliferation, survival, mobility and angiogenesis. Rapamycin and its analogues (CCI-779, RAD001 and AP23573) have specific antagonistic action on the function of mTOR. This leads to inhibition of the downstream signalling elements and results in the cell cycle arrest in the G1 phase. This group of drugs may have a place in Oncology for the treatment of cancers, which occur as a result of increased activity of the PI3 kinase/Akt/m-TOR pathway. The basic structure of the pathway was reviewed in this article, together with results of the clinical studies targeting mTOR for cancer therapy. This is an exciting area for development and poses many challenges to researchers.

PMID:: 15365568; [PubMed - indexed for MEDLINE]
PMCID: PMC2409926

Free PMC Article

Images from this publication.See all images (1) Free text

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Medical

Molecular Biology Databases

SIROLIMUS - HSDB

Libraries

LinkOut Holdings

Supplemental Content

Related citations

Review Mammalian target of rapamycin: a new molecular target for breast cancer. [Clin Breast Cancer. 2003]
Review Mammalian target of rapamycin: a new molecular target for breast cancer.
Mita MM, Mita A, Rowinsky EK. Clin Breast Cancer. 2003 Jun; 4(2):126-37.
Review Current status and challenges associated with targeting mTOR for cancer therapy. [BioDrugs. 2009]
Review Current status and challenges associated with targeting mTOR for cancer therapy.
Dowling RJ, Pollak M, Sonenberg N. BioDrugs. 2009; 23(2):77-91.
Review The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy. [Cell Mol Biol Lett. 2005]
Review The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy.
Janus A, Robak T, Smolewski P. Cell Mol Biol Lett. 2005; 10(3):479-98.
Review Mammalian target of rapamycin is a promising target for novel therapeutic strategy against cancer. [J BUON. 2006]
Review Mammalian target of rapamycin is a promising target for novel therapeutic strategy against cancer.
Bjelogrlić SK, Srdić T, Radulović S. J BUON. 2006 Jul-Sep; 11(3):267-76.
Review New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists. [Breast Cancer Res. 2004]
Review New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists.
Carraway H, Hidalgo M. Breast Cancer Res. 2004; 6(5):219-24. Epub 2004 Aug 12.

See reviews... See all...

Cited by 22 PubMed Central articles

An evaluation tool for FKBP12-dependent and -independent mTOR inhibitors using a combination of FKBP-mTOR fusion protein, DSC and NMR. [Protein Eng Des Sel. 2011]
An evaluation tool for FKBP12-dependent and -independent mTOR inhibitors using a combination of FKBP-mTOR fusion protein, DSC and NMR.
Sekiguchi M, Kobashigawa Y, Kawasaki M, Yokochi M, Kiso T, Suzumura K, Mori K, Teramura T, Inagaki F. Protein Eng Des Sel. 2011 Nov; 24(11):811-7. Epub 2011 Sep 6.
Astaxanthin Improves Stem Cell Potency via an Increase in the Proliferation of Neural Progenitor Cells. [Int J Mol Sci. 2010]
Astaxanthin Improves Stem Cell Potency via an Increase in the Proliferation of Neural Progenitor Cells.
Kim JH, Nam SW, Kim BW, Choi W, Lee JH, Kim WJ, Choi YH. Int J Mol Sci. 2010; 11(12):5109-19. Epub 2010 Dec 9.
α-TEA cooperates with MEK or mTOR inhibitors to induce apoptosis via targeting IRS/PI3K pathways. [Br J Cancer. 2011]
α-TEA cooperates with MEK or mTOR inhibitors to induce apoptosis via targeting IRS/PI3K pathways.
Tiwary R, Yu W, Sanders BG, Kline K. Br J Cancer. 2011 Jan 4; 104(1):101-9. Epub 2010 Nov 30.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound
PubChem chemical compound records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records. Multiple substance records may contribute to the PubChem compound record.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
References for this PMC Article
Citation referenced in PubMed article. Only valid for PubMed citations that are also in PMC.
Substance
PubChem chemical substance records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Free in PMC
Free full text articles in PMC
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Targeting the mammalian target of rapamycin (mTOR): a new approach to treating c...
Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer.
Br J Cancer. 2004 Oct 18 ;91(8):1420-4.

PubMed
Tumor development under angiogenic signaling: a dynamical theory of tumor growth...
Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy.
Cancer Res. 1999 Oct 1 ;59(19):4770-5.

PubMed
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for ad...
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Cancer. 2003 Nov 1 ;98(9):1802-10.

PubMed
GATA-3 maintains the differentiation of the luminal cell fate in the mammary gla...
GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland.
Cell. 2006 Dec 1 ;127(5):1041-55.

PubMed
Systemic endocrine instigation of indolent tumor growth requires osteopontin.
Systemic endocrine instigation of indolent tumor growth requires osteopontin.
Cell. 2008 Jun 13 ;133(6):994-1005.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to:

Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer.

Source

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Molecular Biology Databases

Libraries

Supplemental Content

Related citations

Cited by 22 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information